Atezolizumab and Pre-Surgical Brain Radiation Therapy for Glioblastoma Multiforme
Public ClinicalTrials.gov record NCT05423210. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Pilot Study to Evaluate the Immunogenic Effects of Window-of-Opportunity Fractionated Stereotactic Radiotherapy Combined With Atezolizumab for Patients With Newly Diagnosed WHO CNS Grade 4 Glioma (Glioblastoma Multiforme)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a single-arm pilot study that will recruit 12 patients with newly diagnosed Glioblastoma, a malignant brain tumor with a poor prognosis. Patients will be treated with fractionated stereotactic radiotherapy (FSRT) for 2 weeks, in addition to two doses of Atezolizumab (Tecentriq), an FDA approved PD- L1 inhibitor drug, 840 mg IV, at the beginning and at the end of the two-week time period, concomitantly with FSRT. After this initial two weeks treatment the patients will undergo craniotomy and maximal safe resection as per normal care for a GB. After surgery patients will follow the normal care for glioblastoma in addition to Atezolizumab 840 mg IV q2 weeks for the duration of adjuvant treatment.
Study identification
- NCT ID
- NCT05423210
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Early Phase 1
- Enrollment
- 12 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 24, 2022
- Primary completion
- Jul 31, 2027
- Completion
- Jul 31, 2029
- Last update posted
- Dec 21, 2025
2022 – 2029
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Stony Brook University Hospital | Stony Brook | New York | 11794 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Glioblastoma Multiforme trials
Other public records listing Glioblastoma Multiforme. Sorted by last update posted; newest first. Not a recommendation.
- NCT01837862: A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas Active, not recruiting
- NCT04900792: A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma Active, not recruiting
- NCT05864976: Neurosurgical Neuronavigation Using Resting State MRI and Machine Learning Recruiting
- NCT02177578: Subventricular Zone (SVZ) and Temozolomide in Glioblastoma Multiforme Active, not recruiting
- NCT05120284: Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM) Active, not recruiting
- NCT06011109: Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05423210, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 21, 2025 · Synced Jul 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05423210 live on ClinicalTrials.gov.